# A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19

> **NCT04433013** · PHASE3 · WITHDRAWN · sponsor: **Nanyang Technological University**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Lianhua Qingwen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04433013
- **Lead sponsor:** Nanyang Technological University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07
- **Primary completion:** 2020-12
- **Final completion:** 2021-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to find suitable site Principal Investigator. This study did not start and was withdrawn as of Aug 2020 (have updated as of Sept 2020, please proceed to update the status of study withdrawal accordingly)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433013, "A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04433013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*